These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 18700956

  • 1. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
    Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M.
    BMC Vet Res; 2008 Aug 13; 4():32. PubMed ID: 18700956
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
    Giantin M, Vascellari M, Morello EM, Capello K, Vercelli A, Granato A, Lopparelli RM, Nassuato C, Carminato A, Martano M, Mutinelli F, Dacasto M.
    J Vet Diagn Invest; 2012 Jan 13; 24(1):116-26. PubMed ID: 22362941
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
    Thamm DH, Turek MM, Vail DM.
    J Vet Med Sci; 2006 Jun 13; 68(6):581-7. PubMed ID: 16820715
    [Abstract] [Full Text] [Related]

  • 10. Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
    Halsey CHC, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ.
    Vet Pathol; 2017 May 13; 54(3):387-394. PubMed ID: 28129097
    [Abstract] [Full Text] [Related]

  • 11. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
    De Vos S, Demeyere K, De Cock H, Devriendt N, Schwarzkopf I, Fortrie R, Roggeman T, Meyer E, De Spiegelaere W, de Rooster H.
    Res Vet Sci; 2022 Dec 10; 151():90-95. PubMed ID: 35872552
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mutation and methylation status of KIT and TP53 in canine cutaneous and subcutaneous mast cell tumours.
    Vozdova M, Kubickova S, Fictum P, Cernohorska H, Fröhlich J, Rubes J.
    Vet Comp Oncol; 2020 Sep 10; 18(3):438-444. PubMed ID: 31574575
    [Abstract] [Full Text] [Related]

  • 15. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH, Mauldin EA, Vail DM.
    J Vet Intern Med; 1999 Sep 10; 13(5):491-7. PubMed ID: 10499735
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
    Thompson JJ, Yager JA, Best SJ, Pearl DL, Coomber BL, Torres RN, Kiupel M, Foster RA.
    Vet Pathol; 2011 Jan 10; 48(1):169-81. PubMed ID: 21160022
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.